Ann: Appendix 4C - 31 December 2018, page-14

2018 was a poor year for Bio-Gene in many respects.

It listed on the back of the Virbac collaboration which was terminated by Virbac,

The filing of IRAC application by quarter 4 never happened - New Mode of Action.
There was an expectation of 2 new partnership agreements in 2018 and there was none.
The mosquito results from Purdue University went missing although we were assured they were excellent by Catherine Hill when she visited earlier last year..

A presentation was released in October and the word "imminent" used for new deals all coincidently just prior to the option expiry - not a good look in my mind.

The last quarterly refers to samples having been sent to interested parties. That seems a long way off from any  "imminent" commercial agreements/collaborations.

There has been no Director buying at these depressed prices. Apparently they have enough exposure. I would have thought if they were confident this company is going to be successful (especially if they believed their own rhetoric which the market is supposed to believe) then they couldn't have enough shares.